The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib study of combined angiogenesis blockade with REGN910 (SAR307746), a selective monoclonal antibody (MAb) against angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid tumor malignancies.
Lieve Adriaens
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Kyriakos P. Papadopoulos
Consultant or Advisory Role - Regeneron
Research Funding - Regeneron
Donna M. Graham
No relevant relationships to disclose
Amita Patnaik
Research Funding - Regeneron
Albiruni R.A. Razak
No relevant relationships to disclose
Anthony W. Tolcher
Consultant or Advisory Role - Regeneron (U); Sanofi (U)
Lillian L. Siu
Employment or Leadership Position - Agios (I); Bayer (Other); Boehringer Ingelheim; Bristol-Myers Squibb; Celgene (Other); EntreMed (I); GlaxoSmithKline (Other); Merck (Other); Novartis (Other); Pfizer Inc. (Other); Regeneron (Other)
Consultant or Advisory Role - Boehringer Ingelheim; Oncoethix
Stock Ownership - Agios (I); EntreMed (I); Rigel Pharmaceuticals Inc. (I)
Drew Warren Rasco
Research Funding - Regeneron
Pamela Trail
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Carrie M. Brownstein
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Israel Lowy
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron